This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

HRT - equivalence options for different doses of transdermal oestradiol

Authoring team

Equivalence options for different doses of transdermal oestradiol

  • Evorel (25/50/75/100)
  • Estradot patches (25/50/75/100)
  • Estraderm patches (25/50/75/100)
  • Femseven mono (50/75/100)
  • Progynova TS (50/100)
  • For a dose of 25 can use half a patch of 50.
  • For a dose of 75 can use 3/4 of a patch of 100

  • Alternatively, could switch to a gel preparation as Oestrogel or Sandrena or Lenzetto spray to take with current progestogen intake as above:
    • If taking Evorel 25: Oestrogel one measure a day would give an equivalent.
    • If taking Evorel 50: Oestrogel one measure twice a day would give an equivalent.
    • If taking Evorel 75: Oestrogel three measures a day (2am and 1pm or vice versa) would give an equivalent.
    • If taking Evorel 100: Oestrogel 4 measures a day (2am and 2pm) would give an equivalent.
    • Or Sandrena gel:
      • If taking Evorel 25: 0.5mg Sandrena sachet a day would give an equivalent.
      • If taking Evorel 50: 1mg Sandrena sachet a day would give an equivalent.
      • Or Lenzetto three sprays (40mcgm) equivalent to two measures of Oestrogel or 50 microgram patch

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.